A Phase 1 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP1601 and the Effect of Food on ZSP1601 Pharmacokinetics in Chinese Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs ZSP-1601 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Guangdong Zhongsheng Pharmaceutical
- 12 Aug 2019 Status changed from recruiting to completed.
- 31 Jul 2018 Planned number of patients changed from 100 to 94.
- 15 Jan 2018 New trial record